StemCell Therapy

DUBLIN, Feb. 7, 2020 /PRNewswire/ -- The "Molecular Diagnostics Global Market - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

The global molecular diagnostics global market is estimated to reach $18,668.9 million by 2026 growing at a high single-digit CAGR from 2019 to 2026.

Among the overall molecular diagnostic market is increasing prevalence of different types of cancers, infectious diseases, genetic disorders and other diseases, increasing awareness in personalized medicine and companion diagnostics and also growth in the point of care testing and sequencing-based tests and other molecular techniques.

Molecular diagnostics plays a pivotal role in the evaluation of the disease and for the effective response for specific therapy. However, the complex regulations for the approval of molecular diagnostic tests, availability of competing/alternative technologies, high cost of the tests, and also a shortage of technical experts are some of the restrains for the growth of the molecular diagnostics market.

Segment Highlights

The molecular diagnostics global market is segmented based on product, technology, application and end-users.

The product market is further categorized into instruments, consumables and software and services. As per research estimations, the consumable global market commanded the largest revenue in 2019 and is projected to grow at double-digit CAGR from 2019 to 2026.

The molecular diagnostics global market by technology is divided into PCR, microarray and microfluidics, isothermal nucleic acid amplification tests, in-situ hybridization, NGS and other technologies. PCR accounted for the largest revenue in 2019 and is expected to grow at a double-digit CAGR from 2019 to 2026 due to low cost and is a common and indispensable technique used for diagnosis when compared to other instruments such as NGS and also due to technological advancements in PCR and their subtypes such as digital droplet PCR with precise and highly sensible results.

The molecular diagnostics by application market is classified into infectious diseases, oncology, genetic testing, transplantation, blood screening and other diseases such as metabolic disorders and diseases associated with the central nervous system. The largest revenue was contributed by infectious diseases segment in 2019 and this market is expected to grow at a high single-digit CAGR from 2019 to 2026 due to high incidence of bacterial and viral infections.

Infectious diseases are further segmented into bacterial, viral and other diseases. The viral diseases commanded the largest revenue in 2019 and the market is expected to grow at a strong double-digit CAGR from 2019 to 2026. Viral diseases are further segmented into HIV, hepatitis, HPV, influenza and other viral infections. Among these, HIV accounted for the largest revenue in 2019 and is expected to grow at a double-digit CAGR from 2019 to 2026.

The bacterial diseases are sub-segmented into sexually transmitted diseases (STD) caused by bacteria, hospital acquired infections, tuberculosis and other diseases such as sepsis, pneumonia and meningitis, etc. Sexually transmitted disease accounted for the largest revenue in 2019 and is expected to grow at high single-digit CAGR from 2019 to 2026. The growth is attributed to the increased awareness about the molecular based kits available for the diagnoses of STDs and also increases in the prevalence.

Under genetic testing segment the market is segmented into NIPT, cystic fibrosis and other genetic testing, among them NIPT commanded the largest revenue in 2019 and is expected to grow at a double digit CAGR from 2019 to 2026 as NIPT provides a safer alternative to invasive tests and it analyzes fetal cell-free DNA (cfDNA) from the mother's circulation, making early detection of genetic disorders such as Down syndrome and other chromosomal aberrations easier.

Based on the type of cancer, the oncology market is segmented into lung, breast, colorectal, prostate, ovarian, melanoma, ovarian and other cancers. The largest revenue under oncology was accounted for by colorectal cancer with the revenue in 2019 and breast cancer is expected to grow at double-digit CAGR from 2019 to 2026.

Based on the cancer care, the oncology segment is subdivided into early screening, companion diagnostics, prognosis and recurrence. Early screening contributed for the largest revenue in 2019 and companion diagnostics is expected to grow at double-digit CAGR from 2019 to 2026. Further, the transplantation market is segmented into kidney, heart and other transplantation such as lung and pancreatic transplantation. Among them, kidney transplantation commanded the largest revenue in 2019.

Molecular diagnostics end-users market is segmented into hospitals, clinical/centralized laboratories, academics and research and other end users. Clinical/centralized laboratories accounted for the largest revenue due to the rapid adoption of technology and economies of scale in testing a large number of samples collected from affiliated hospitals.

Geographical wise, North America region commanded the largest revenue in 2019 and is expected to grow at a mid-single-digit CAGR from 2019 to 2026 owing to the high demand for early detection, treatment selection and prevention of diseases with advanced technology due to diseases associated with the lifestyle. However, the Asia-pacific region is expected to grow at an early teen CAGR from 2019 to 2026 attributing to increasing awareness of the molecular based test for the better outcome.

Competitive Landscape

The molecular diagnostics global market is a competitive market and all the existing players in this market are involved in developing new and advanced molecular based techniques for diagnosis to maintain their market shares and also acquiring companies for product expansion.

Some of the key players in molecular diagnostics global market are Abbott Laboratories (U.S.), F.Hoffmann-LA Roche AG (Switzerland), BioMerieux (France), Qiagen (Netherlands) Exact Sciences (U.S.), Grifols (Spain), Danaher Corporation (U.S.), Hologic, Inc. (U.S.), and Myriad Genetics, Inc. (U.S.)

Key Topics Covered

1 Executive Summary

2 Introduction

3 Market Analysis3.1 Introduction3.2 Market Segmentation3.3 Factors Influencing Market3.3.1 Drivers and Opportunity3.3.1.1 Increasing Incidence of Infectious Diseases3.3.1.2 Rising Incidence of Cancer and Non-Infectious Diseases3.3.1.3 Technological Advancements3.3.1.4 Favorable Reimbursements3.3.1.5 Investment by Major Players3.3.2 Restraints and Threats3.3.2.1 Lack of Skilled Professionals3.3.2.2 High Cost of Molecular Diagnostics Products3.3.2.3 Lack of Standardization of the Molecular Diagnostics Test3.3.2.4 Stringent and Time-Consuming Regulatory Issues3.3.2.5 Lack of Reproducibility and Repeatability3.3.2.6 Biochemical and Alternative Tests3.4 Market Share Analysis3.4.1 Molecular Diagnostics Global Market Share Analysis3.4.2 Molecular Diagnostics In Infectious Diseases Market Share3.5 Regulatory Affairs3.5.1 U.S.3.5.2 Europe3.5.3 China3.5.4 India3.5.5 Japan3.5.6 Australia3.5.7 South Korea3.6 Reimbursement Scenario3.7 Clinical Trials3.7.1 Ctdna Clinical Trials3.7.2 Cfdna Clinical Trials3.7.3 Circulating Tumor Cells3.7.4 Companion Diagnostics3.8 Latest and Upcoming Products3.9 Porter's Five Force Analysis3.10 Funding Scenario

4 Market Sizing4.1 U.S.Cancer Care Market Sizing Information4.1.1 Oncology Testing4.1.1.1 Early Screening4.1.1.2 Companion Diagnostics4.1.1.3 Prognosis Monitoring4.1.1.4 Recurrence Monitoring4.1.2 Non-Invasive Prenatal Screening (NIPT)4.1.3 Transplantation Diagnostics

5 Molecular Diagnostics Global Market, by Products5.1 Introduction5.2 Instruments5.3 Consumables5.4 Software and Services

6 Molecular Diagnostics Global Market by Technology6.1 Introduction6.2 PCR6.3 Microfluidics and Microarray6.4 Isothermal Nucleic Acid Amplification Technology (INAAT)6.5 In-Situ Hybridization6.6 Next Generation Sequencing (NGS)6.7 Others

7 Molecular Diagnostics Global Market, by Application7.1 Introduction7.2 Infectious Diseases7.2.1 Bacterial Diseases7.2.1.1 Sexually Transmitted Diseases7.2.1.2 Hospital Acquired Infections7.2.1.3 Tuberculosis7.2.1.4 Others7.2.2 Viral Diseases7.2.2.1 Hiv7.2.2.2 Hepatitis7.2.2.3 Influenza7.2.2.4 Human Papiloma Virus (HPV)7.2.2.5 Other Viral Diseases7.2.3 Other Infectious Diseases7.3 Genetic Testing7.3.1 Non-Invasive Prenatal Testing (NIPT)7.3.2 Cystic Fibrosis7.3.3 Other Genetic Diseases7.4 Oncology Testing7.4.1 Cancer Types7.4.1.1 Introduction7.4.1.2 Lung Cancer7.4.1.3 Breast Cancer7.4.1.4 Colorectal Cancer7.4.1.5 Prostate Cancer7.4.1.6 Melanoma7.4.1.7 Ovarian Cancer7.4.1.8 Others7.4.2 Cancer Care7.4.2.1 Introduction7.4.2.2 Early Screening7.4.2.3 Companion Diagnostics7.4.2.4 Prognosis Monitoring7.4.2.5 Recurrence Monitoring7.5 Transplantation7.5.1 Kidney Transplantation7.5.2 Heart Transplantation7.5.3 Other Transplantation7.6 Blood Screening7.7 Other Diseases

8 Molecular Diagnostics Global Market, by End Users8.1 Introduction8.2 Hospitals8.3 Clinical/Centralized Laboratories8.4 Academic and Research8.5 Others

9 Molecular Diagnostics Global Market, by Region9.1 Introduction9.2 North America9.2.1 U.S.9.2.2 Rest of North America9.3 Europe9.3.1 France9.3.2 Germany9.3.3 Italy9.3.4 Rest of Europe9.4 Asia-Pacific Region9.4.1 China9.4.2 India9.4.3 Japan9.4.4 Rest of Asia-Pacific9.5 Rest of the World9.5.1 Brazil9.5.2 Rest of Latin America9.5.3 Middle East and Others

10 Competitive Landscape10.1 Introduction10.2 Approvals10.3 Collaborations10.4 Acquisitions10.5 New Product Launches10.6 Others

11 Major Companies11.1 Abbott Laboratories11.1.1 Overview11.1.2 Financials11.1.3 Product Portfolio11.1.4 Key Developments11.1.5 Business Strategy11.1.6 SWOT Analysis11.2 Becton, Dickinson and Company11.3 BioMerieux11.4 Danaher Corporation11.5 Exact Sciences Corporation11.6 Grifols, S.A.11.7 Hologic, Inc.11.8 Myriad Genetics, Inc.11.9 Qiagen N.V.11.10 F. Hoffmann-La Roche Ltd.

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/47ly96

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Originally posted here:
Molecular Diagnostics Industry Report, 2020 to 2026 - Analysis by Product, Technology, Application, End-user and Region - PRNewswire

This entry was posted on February 8, 2020 at 9:51 pm and is filed under Molecular Genetics. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |